InvestorsHub Logo
Followers 73
Posts 16330
Boards Moderated 3
Alias Born 04/24/2000

Re: Giovanni post# 1660

Wednesday, 12/06/2017 5:22:39 PM

Wednesday, December 06, 2017 5:22:39 PM

Post# of 2104
SA piece after Madrigal's phase IIb sucess:

NASH drug developers in the red after Madrigal's mid-stage success with MGL-3196
Dec. 6, 2017 12:37 PM ET|By: Douglas W. House, SA News Editor
Investors are swarming over Madrigal Pharmaceuticals (MDGL +79.8%) after it reported positive results from a Phase 2 clinical trial assessing MGL-3196 in NASH patients. Certain would-be NASH players have been brushed aside in early trading.
Selected tickers: (MNOV +0.9%)(GLMD)(RGLS -2.2%)(ICPT +0.4%)(CNAT -2.4%)(VBLT +1.6%)(GALT -8.7%)(SHPG -1.5%)(AGN +0.3%)(HZNP -1.2%)(OTCPK:GNFTF -5%)(VKTX +2.6%)


I'm not familiar with MDGL's entry...whether it's a targeted approach for a single issue (NASH), or a multi-faceted potential like CNAT. CNAT's game is for combination therapies focused on multiple liver issues not exclusively NASH.
From CNAT Website:

We believe that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease and potentially provide treatment options in multiple areas of liver disease.

(as well as other organs eventually).

Theo ;-)